The European Commission has approved GSK’s ViiV Healthcare unit’s HIV-focused cabotegravir injection and long-acting tablets, the British drugmaker said on Tuesday.
EUROPEAN COMMISSION HEAD URSULA VON DER LEYEN PROVIDES AID TO FLOODED SLOVENIA DURING VISIT
Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents who weigh at least 77.16 kg, according to the company.
It is sold under the brand name Apretude and is approved for use in the United States, Australia, Zimbabwe, South Africa, Malawi, Botswana and Brazil.
CLICK HERE TO GET THE FOX NEWS APP